Kseniya Simpson
Principal at Hatteras Venture Partners
Raleigh-Durham-Chapel Hill Area
Overview
Work Experience
Principal
2024 - Current
Associate
2022 - 2024
Senior Analyst
2021 - 2022
Analyst
2019 - 2020
Venture Capital Multiplier Fund is a venture capital firm
Board Observer
2023
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world’s most lethal diseases.
Raised $15,900,000.00 from SOSV, Hatteras Venture Partners, Alexandria Venture Investments, Draper Associates, Sigma Group and Morpheus Ventures.
Board Observer
2022
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Raised $36,000,000.00 from Hatteras Venture Partners, Canaan Partners and OrbiMed.
Board Observer
2022
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Raised $85,000,000.00 from UPMC Enterprises, Amgen Ventures, CureDuchenne Ventures, New Enterprise Associates, 4BIO Capital, UCB Ventures, Takeda Ventures, JDRF T1D Fund, Northpond Ventures and Hatteras Venture Partners.
Board Observer
2022
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Raised $85,775,048.00 from Hatteras Venture Partners, Bios Partners, Correlation Ventures, Hatteras Venture Partners, Aju IB Investment, InFocus Capital Partners, Access Biotechnology and ExSight Ventures.
Board of Directors
2021
Board Observer
2020 - 2022
NASDAQ: VIGL IPO: 01/2022
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Raised $180,000,000.00 from Sanofi.
Strategy Consultant
2017 - 2018
Associate Strategy Consultant
2016 - 2017
Postdoctoral Fellow
2015 - 2015
Laboratory of Dr. Joseph DeSimone (currently Professor of Translational Medicine and Chemical Engineering at Stanford University)
Licensing Intern
2013 - 2015